Matinas BioPharma (MTNB) Reports In-Line Q1 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- S&P 500 ends down after Trump says Iran deal is 'over'
- Oil settles at multi-week high as US-Iran truce buckles under fresh hostilities
- Nvidia is up just 3% YTD while SOX surges 82% — what’s holding it back?
- BofA says S&P 500 technicals point to corrective Q3
- Alibaba rallies 12% after report of narrowing losses sparks pre-earnings optimism
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- GameStop stockholders approve share count increase to 2.5 billion
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
May 11, 2020 4:05 PM EDTENHANCE-IT study of MAT9001 against Vascepa® set to resume in June 2020
EnACT study of MAT2203 in cryptococcal meningitis expected to resume in June 2020
Management to host conference call today, Monday, May 11th, at 4:30 p.m. ET
BEDMINSTER, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER:... More
